Emmaus Life Sciences (OTCMKTS:EMMA) Announces Earnings Results

Emmaus Life Sciences (OTCMKTS:EMMA – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $1.89 million during the quarter.

Emmaus Life Sciences Stock Performance

Shares of Emmaus Life Sciences stock opened at $0.04 on Friday. The business has a 50-day simple moving average of $0.05 and a 200-day simple moving average of $0.02. Emmaus Life Sciences has a one year low of $0.01 and a one year high of $0.09. The company has a market cap of $2.46 million, a PE ratio of -0.39 and a beta of 11.25.

Emmaus Life Sciences Company Profile

(Get Free Report)

Emmaus Life Sciences is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly sickle cell disease. Its main product, Endari, is an oral powder formulation of L-glutamine approved in the United States to reduce acute complications of sickle cell disease in adults and children aged 5 years and older. The U.S. Food and Drug Administration approved Endari in 2017. Emmaus has also pursued development and commercialization opportunities for its products in markets outside the United States.

Read More

Earnings History for Emmaus Life Sciences (OTCMKTS:EMMA)

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.